North America Biodefense Market to 2027 - Regional Analysis and Forecasts by North America Biodefense Market to 2027 - Regional Analysis and Forecasts by Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others); and Country
North America, the biodefense market, is anticipated to reach US$ 3,357.83 Mn in 2027 from US$ 1,569.29 Mn in 2019. The market is projected to grow with a CAGR of 10.1% from 2020-2027.
The biodefense market is growing primarily due to the presence of favorable government initiatives and increase in the number of naturally occurring outbreaks. Restraining factors, such as limited reach of biodefense organizations, are likely to damage the growth of the market in the coming years. On the other hand, increasing adoption of technologies is expected to have a positive impact on the growth of the North American biodefense market in the coming years.
Disease outbreaks are usually caused by an infection, transmitted through person-to-person contact, animal-to-person contact, or from the environment or other media. Emerging infectious diseases are infections that have recently appeared within a population and are rapidly increasing or threaten to grow shortly. The World Health Organization warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since the 1970s, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola, avian flu, swine flu, zika, and most recently, coronavirus. Moreover, as per CDC estimates, between 2016 and 2017, nearly 30 Million people suffered from influenza in the U.S. Biodefense techniques, such as vaccinations against influenza; helps reduce the illness by 17% and medical visits and hospitalizations by 18 to 19% respectively. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the market development. For instance, due to coronavirus outbreak, more than 210,000 cases have now been reported to WHO, and more than 9,000 people have lost their lives as of 20 March 2020. Further, on March 18, 2020 Emergent BioSolutions signed development and manufacturing agreement with Vaxart for their experimental oral vaccine candidate for Coronavirus Disease.
The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies, For instance, the NIH‐supported research on infectious diseases and biodefense builds and maintains a base of fundamental knowledge about contagious and immune‐related diseases and uses that knowledge to develop new and improved diagnostics, therapeutics, and preventive measures, including vaccines.
The growing prevalence of infectious diseases, such as coronavirus Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the market growth.
In 2019, the US accounted for the largest market share in North America biodefense market, and it is also expected to grow at a faster pace over the forecast period. US is an economically advanced country, and the country has the presence of various players that are well established in the biotechnology market. Significant funding by the U.S. military and civilian agencies for biodefense is also one of the key factors responsible for the highest revenue share of the region. Hence, considering the mentioned factors, the biodefense market is expected to grow at a significant pace in the US during the forecast period.
US Biodefense Market Revenue and Forecasts to 2027 (US$ Mn)
Get more information on this report :
NORTH AMERICA CLEAR ALIGNERS – MARKET SEGMENTATION
- Anthrax
- Small pox
- Botulism
- Radiation/Nuclear
- Others
By Geography
- North America
- US
- Canada
- Mexico
Company Profiles
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Biodefense Market – By Product
1.3.2 North America Biodefense Market – By Country
2. North America Biodefense Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Biodefense Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 4.2.1 Biodefense Market - North America PEST Analysis
4.3 Expert Opinion
5. North America Biodefense Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Presence of Favourable Government Initiatives
5.1.2 Increase in the Number of Naturally Occurring Outbreaks
5.2 Key Restraints
5.2.1 Limited Reach of Biodefense Organizations
5.3 Key Market Opportunities
5.3.1 Increasing Adoption of Technologies
5.4 Future Trend
5.4.1 Predictive Analytics to Reshape Biodefense Market
5.5 Impact Analysis
6. Biodefense Market – North America Analysis
6.1 North America Biodefense Market Revenue Forecasts and Analysis
6.2 Market Positioning of Key Players
7. North America Biodefense Market Analysis and Forecasts To 2027 – By Product Type
7.1 Overview
7.2 Biodefense Market Revenue Share, by Product (2019 and 2027)
7.1 Anthrax
7.1.1 Overview
7.1.2 Anthrax: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
7.2 Small pox
7.2.1 Overview
7.2.2 Small pox: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
7.3 Botulism
7.3.1 Overview
7.3.2 Botulism: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Radiation/Nuclear
7.4.1 Overview
7.4.2 Radiation/Nuclear: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
8. Biodefense Market Revenue and Forecasts To 2027 – Geographical Analysis
8.1 North America Biodefense Market Revenue and Forecasts To 2027
8.1.1 Overview
8.1.2 North America: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.3 North America: Biodefense Market, by Product, 2018–2027 (USD Million)
8.1.4 North America: Biodefense Market, by Country, 2019 & 2027 (%)
8.1.5 US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.5.1 US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.5.2 US: Biodefense Market, by Product Type, 2018–2027 (USD Million)
8.1.6 Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.6.1 Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.6.2 Canada: Biodefense Market, by Product Type, 2018–2027 (USD Million)
8.1.7 Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.7.1 Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
8.1.7.2 Mexico: Biodefense Market, by Product Type, 2018–2027 (USD Million)
9. North America Biodefense Market Industry Landscape
9.1 Overview
9.2 Growth Strategies in The Biodefense Market, 2016-2020
9.3 Inorganic Growth Strategies
9.3.1 Overview
9.4 Organic Growth Strategies
9.4.1 Overview
10. COMPANY PROFILES
10.1 Bavarian Nordic
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Alnylam Pharmaceuticals, Inc.
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 SIGA Technologies
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Emergent BioSolutions Inc.
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Cleveland Bio Labs
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Dynavax Technologies
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Elusys Therapeutics, Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Soligenix
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Altimmune
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Pluristem
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Biodefense Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 2. US Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 3. Canada Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 4. Mexico Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 5. Recent Inorganic Growth Strategies In The Biodefense Market
Table 6. Recent Organic Growth Strategies In The Biodefense Market
Table 7. Glossary of Terms, Skin aesthetic devices market
LIST OF FIGURES
Figure 1. Biodefense Market Segmentation
Figure 2. North America Biodefense Market Overview
Figure 3. Anthrax Segment Held Largest Share of Product Segment in Biodefense Market
Figure 4. US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. North America Biodefense Market- Leading Country Markets (US$ Mn)
Figure 6. North America Biodefense Market, Industry Landscape
Figure 7. Biodefense Market - North America PEST Analysis
Figure 8. Biodefense Market Impact Analysis of Drivers and Restraints
Figure 9. North America Biodefense Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 10. Market Positioning Of Key Players In Global Biodefense Market
Figure 11. Biodefense Market Revenue Share, by Product (2019 and 2027)
Figure 12. Anthrax: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. Small pox: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Botulism: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Radiation/Nuclear: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. Others: Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. North America: Biodefense Market, by Key Country – Revenue (2019) (USD Million)
Figure 18. North America Biodefense Market Revenue and Forecast to 2027 (USD Million)
Figure 19. North America: Biodefense Market, by Country, 2019 & 2027 (%)
Figure 20. US: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
Figure 21. Canada: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
Figure 22. Mexico: Biodefense Market – Revenue and Forecast to 2027 (USD Million)
Figure 23. Growth Strategies in the Biodefense Market, 2016-2020
The List of Companies - North America Biodefense Market
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America biodefense market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.